Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Abstract
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [23]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cited by
Items 401–500 of 678
Long, J., Liu, L., Yang, X., Lu, X., & Qin, L. (2023) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.39.6.7944 · Cited by 3
Lee, C.-C., Hwang, J.-I., Chang, K., Lin, Y.-J., Chao, C. C., CHENG, T., Chen, Y., & Hsueh, K. (2023) · Clinical Radiology · doi:10.1016/j.crad.2023.09.015 · Cited by 3
Hsiao, Y., Sou, F., Wang, J., Chen, Y., Tsai, M., Hu, T., Hung, C., Chen, C., & Kuo, Y. (2023) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12757 · Cited by 3
“3,4 8 From an economic aspect, although treatment response of combined immunotherapy is more effective than TKI, the high cost of atezolizumab plus bevacizumab confines its clinical application, leaving sorafenib or lenvatinib as the most common treatment for advanced HCC in real-life clinical…”
BackgroundXu, Y., Fu, S., Liu, K., Ye, M., & Wu, J. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s420371 · Cited by 3
Quan, B., Li, J., Mi, H., Li, M., Liu, W., Fan, Y., Chen, R., Shan, Y., Xu, P., Ren, Z., et al. (2024) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-024-01003-2 · Cited by 6
“HAIC was listed in the Japan Society of Hepatology guidelines in 1995 and accepted as an interventional therapy for advanced HCC by the Chinese Society of Clinical Oncology [15, 16].”
Jia-Yong, S., Wang, H., Ding-Wen, L., Qing-Qing, C., Yu-Tong, C., Jun-Shao, T., Mei, C., Tian, W., Xie, R.-W., Liang, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27355 · Cited by 3
“The most recent guidelines from Japan [17] and the USA [18] recommend assigning HCC patients who experience tumor rupture to stage T4 in the TNM system.”
BackgroundWang, Z., Ouyang, J., Jia, B., Zhou, Y., Yang, Y., Li, X.-T., Li, Q., & Zhou, J. (2024) · Cancer Medicine · doi:10.1002/cam4.7068 · Cited by 3
Chen, Y.-X., Zhang, J.-X., Zhou, C., Liu, J., Liu, S., Shi, H., Zu, Q., & Cheng, Y. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01036-4 · Cited by 3
“Nevertheless, 37–49.5% of patients have a poor or even no response to TACE treatment due to the high heterogeneity of HCC [3–5].”
InfluentialJiang, X. M., Aljbri, A., Liu, J., Shang, L., Tian, Y., & Shao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1401882 · Cited by 3
Wu, Y., Zhuo, C., Yuan, L., Luo, Z., Lu, L., Wang, J., Tang, Q., Phipps, M. M., Nahm, W. J., Facciorusso, A., et al. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-230 · Cited by 3
Tsuruoka, M., Ninomiya, M., Inoue, J., Iwata, T., Sano, A., Sato, K., Onuki, M., Sawahashi, S., & Masamune, A. (2024) · Oncology · doi:10.1159/000540438 · Cited by 5
Yamamoto, A., Nagao, M., Inoue, A., Nakao, R., Sakai, R., Nishina, Y., Morita, S., Sakai, A., Kogiso, T., Kaneko, K., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14113 · Cited by 3
Li, J., Liu, Y., Qiu, Y., Qu, C., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1487353 · Cited by 3
Qiu, Z., Cai, H., Wu, Y., Dai, J.-L., Qi, W., Chen, C., Xu, Y.-Q., Li, C., & Wen, T. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03588-6 · Cited by 4
Tsuji, Y., Namisaki, T., Takaya, H., Nishimura, N., Noguchi, R., Asada, S., Shibamoto, A., Kubo, T., Iwai, S., Tomooka, F., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08884-5 · Cited by 3
“The 2021 JSH Consensus Statement Recommendations state that the recommended cutoff values of AFP, AFP-L3 fraction, and des-γ-carboxy-prothrombin (DCP) for HCC surveillance and diagnosis are 10 ng/mL, 10%, and 40 mAU/mL, respectively [5].”
InfluentialChen, S., Yu, W., Wang, X. J., & Liu, W. (2025) · Hepatic Oncology · doi:10.1080/20450923.2025.2516994 · Cited by 3
Dong, S., Xiong, Z., Yangyang, L., Yan, L., Deng, H., Wang, S., Meng, X., & Liu, T. (2021) · Medicine · doi:10.1097/md.0000000000027497 · Cited by 3
A new era for hepatocellular carcinoma
Memeo, R., Pisani, A. R., Ammendola, M., de’Angelis, N., & Inchingolo, R. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-10 · Cited by 3
Minami, Y. (2023) · Journal of Medical Ultrasonics · doi:10.1007/s10396-022-01273-9 · Cited by 3
“In Japan, screening conducted every 3–4 months using US and serum tumor markers such as alpha-fetoprotein * Yasunori Minami minkun@med.kindai.ac.jp 1 Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi Osaka-Sayama, Osaka 589-8511, Japan 1 3 (AFP), AFP-L3, and des-…”
BackgroundInfluentialSelf-citationMoriya, K., Nagamatsu, S., Uejima, M., & Matsuo, H. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-760 · Cited by 3
“On the contrary, the consensus-based guidelines from Japan and Taiwan propose HAIC as one of the treatment options for the advanced PVTT-HCC (VP3 and VP4) (3,4).”
InfluentialOptions and survival benefits of conversion therapy for unresectable hepatocellular carcinoma
She, W. H., & Cheung, T. T. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i18.2479 · Cited by 3
Endo, K., Kakisaka, K., Abe, T., Yusa, K., Nakaya, I., Watanabe, T., Abe, H., Suzuki, A., Yoshida, Y., Oikawa, T., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14084 · Cited by 2
“…progression was observed after ATZ þ BEV therapy, the most appropriate therapy was performed according to the Japanese practice guidelines for HCC. 22 Furthermore, patients receiving the next chemotherapy regimen after discontinuation of ATZ þ BEV treatment were compared using the GS and ECOG ‐…”
Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma
Kudo, M. (2024) · Interventional Radiology · doi:10.22575/interventionalradiology.2023-0035 · Cited by 9
“The Asia-Pacific Primary Liver Cancer Expert Association [25] and the Japan Society of Hepatology [26] published a “ Consensus Statement and Recommendations ” [25, 26].”
Self-citationImaoka, Y., Ohira, M., Kobayashi, T., Honmyo, N., Hamaoka, M., Onoe, T., Takei, D., Oishi, K., Abe, T., Nakayama, T., et al. (2025) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.70010 · Cited by 2
Liang, T., He, Y., Mo, S., Liao, Y., Huang, K., Gao, Q., Shen, X., Yang, C., Liao, X., Qin, W., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14296-5 · Cited by 2
Koroki, K., Ogasawara, S., Yumita, S., Nakagawa, M., Kanzaki, H., Kobayashi, K., Inoue, M., Nakamura, M., Kanogawa, N., Kondo, T., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101509 · Cited by 2
Self-citationCao, Y., Pan, L., Ran, Z., Zhang, W., Li, J., Li, X., Jiao, T., Liu, Z., Wan, T., Tang, H., et al. (2025) · BioScience Trends · doi:10.5582/bst.2025.01162 · Cited by 2
Kee, K., Chen, C., Liu, T., Huang, Y., Hu, J., Chau, G., Chen, K.-H., Chiang, C., Lin, C., Hung, C., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101943 · Cited by 2
Komiyama, Y., Muraoka, M., Iijima, T., Osawa, L., Takada, H., Suzuki, Y., Sato, M., Takano, S., Maekawa, S., Tsuchiya, A., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70013 · Cited by 2
Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Liver International · doi:10.1111/liv.70286 · Cited by 3
Self-citationYu, Z.-C., Shi, Z.-J., Fang, Z.-K., Liu, S., Yu, Y., Wang, K.-D., Huang, D., Shen, G., Zhang, C., & Liang, L. (2025) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2025.116716 · Cited by 2
Kariyama, K., Nouso, K., Hiraoka, A., Tada, F., Ohama, H., Toyoda, H., Yasuda, S., Tada, T., Tanaka, K., Tsuji, K., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70070 · Cited by 2
Self-citationLiu, X., Yin, L., Liu, B., Hou, X., Li, Y., & Liu, R. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s567414 · Cited by 3
“11 Moreover, the Japanese Society for Hepatology (JSH) has directly endorsed HAIC as a standard therapy for HCC patients complicated by PVTT. 30 Molecular targeted agents inhibit tyrosine kinase receptors such as VEGFR and PDGFR, directly suppressing vascular endothelial cell proliferation and reducing the neovascular…”
InfluentialOhara, M., Kozuka, R., Uchida, Y., Iino, C., Sasaki, R., Tojima, H., Kawata, K., Kakizaki, S., Tokumoto, Y., Endo, M., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02345-0 · Cited by 2
Abbas, Z., Gazder, D. P., Hyder, Z., Qadeer, M. A., & Abbas, M. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i2.113673 · Cited by 2
“While American Association for the Study of Liver Diseases guidelines omit PIVKA-II for screening, Japanese protocols endorse its combined use with AFP [15].”
Wu, S., Qiu, F., Zhang, F., Chen, P., Zheng, X., Wei, Q., Zhang, H., Cheng, Q., Shu, A., Li, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1742116 · Cited by 2
“Notably, the Japanese Society of Hepatology (JSH) guidelines have endorsed HAIC as one of the preferred therapeutic strategies for HCC with portal vein involvement (7).”
Chen, X., Huang, M., Liu, R., & Chan, L. W. C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1706375 · Cited by 4
Chen, J.-L., Chen, Y., & Ker, C. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i2.258 · Cited by 2
Ippolito, D., Maino, C., Gatti, M., Marra, P., Faletti, R., Cortese, F., Inchingolo, R., & Sironi, S. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i11.1669 · Cited by 2
Minagawa, T., Itano, O., Kitago, M., Abe, Y., Yagi, H., Hibi, T., Shinoda, M., Ojima, H., Sakamoto, M., & Kitagawa, Y. (2023) · Cancers · doi:10.3390/cancers15082320 · Cited by 2
“It has been noted in the Japanese guidelines for HCC that a curative treatment strategy that takes hepatic functional reserve into account should be designed for recurrent HCC after RFA [4].”
BackgroundSelf-citationIshikawa, T., Hasegawa, I., Hirosawa, H., Honmou, T., Sakai, N., Igarashi, T., Yamazaki, S., Kobayashi, T., Sato, T., Iwanaga, A., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s412642 · Cited by 2
“Radiofrequency ablation (RFA) or surgical resection is recommended for patients with 1 to 3 tumours of ≤ 3 cm.(2) Microwave ablation (MWA) is a recent development in the field of tumour ablation that uses electromagnetic waves to establish a microwave near-field with direct tissue heating.”
BackgroundMethodInfluentialCharacteristics of cabozantinib treatment in advanced hepatocellular carcinoma
Nouso, K., Shiota, S., Fujita, R., Wakuta, A., Kariyama, K., Hiraoka, A., Atsukawa, M., Tani, J., Tada, T., Matsuo, Y., et al. (2023) · Liver Cancer International · doi:10.1002/lci2.74 · Cited by 2
“4,23,24 Therefore, more than half of the patients (59.3”
BackgroundInfluentialSelf-citationWatanabe, Y., Aikawa, M., Oshima, Y., Kato, T., Takase, K., Watanabe, Y., Okada, K., Okamoto, K., & Koyama, I. (2023) · HPB · doi:10.1016/j.hpb.2023.09.002 · Cited by 3
Wen, R., Huang, F., Lin, P., Gao, R., Pang, J., Wu, Y., Yin, H., Tang, Z.-P., Ma, Z., He, Y., et al. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-04043-4 · Cited by 2
Shimizu, R., Ida, Y., & Kitano, M. (2023) · Diagnostics · doi:10.3390/diagnostics13193058 · Cited by 2
“The gross classification of HCC is divided five types [24]:”
BackgroundKang, H., Lee, J. M., Yoon, J. H., Yoo, J., Kim, J. H., & Park, J. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.23.30156 · Cited by 2
Kawanaka, H., Tajiri, K., Muraishi, N., Murayama, A., Nukui, T., & Yasuda, I. (2024) · Case Reports in Gastroenterology · doi:10.1159/000535476 · Cited by 2
Takada, H., Komiyama, Y., Osawa, L., Muraoka, M., Suzuki, Y., Sato, M., Kobayashi, S., Yoshida, T., Takano, S., Maekawa, S., et al. (2024) · Cancers · doi:10.3390/cancers16051036 · Cited by 2
“The appropriate use of BPC when performing local ablation therapies may allow for more precise treatment in a shorter time and safely.”
MethodYamaba, S., Imai, Y., Sugawara, K., Uchida, Y., Fuchigami, A., Uchiya, H., Nakayama, N., & Mochida, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298770 · Cited by 3
“The Japanese clinical practice guideline [4] also recommended sorafenib and lenvatinib as first-line MTAs for patients with unresectable HCC who are unsuitable candidates for atezolizumab plus bevacizumab therapy, such as patients with autoimmune diseases, and regorafenib, ramuciru-mab and…”
Self-citationAi, H., Gong, T., Ma, Y., Ma, G., Ding, W., Ding, W., Wang, W., & Zhao, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1358602 · Cited by 4
Ruan, L., Yu, J., Lu, X., Numata, K., Zhang, D., Liu, X., Li, X., Zhang, M., & Wang, F. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.08.020 · Cited by 2
Shigefuku, R., Iwasa, M., Tanaka, H., Tsukimoto, M., Tamai, Y., Fujiwara, N., Yoshikawa, K., Tameda, M., Ogura, S., & Nakagawa, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195925 · Cited by 2
Systemic Therapy for Hepatocellular Carcinoma
Kinsey, E. N., & Morse, M. A. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.010 · Cited by 4
Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky, V., Gross, M., Madoff, D. C., Duncan, J., Taddei, T. H., Strazzabosco, M., Jaffe, A., & Chapiro, J. (2025) · Clinical Imaging · doi:10.1016/j.clinimag.2025.110438 · Cited by 2
Luo, C., Xiang, H., & Tan, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1543903 · Cited by 2
Shimose, S., Niizeki, T., Iwamoto, H., Tanaka, M., Moriyama, E., Shirono, T., Nakano, M., Kuromatsu, R., Koga, H., & Kawaguchi, T. (2025) · Hepatology Research · doi:10.1111/hepr.14193 · Cited by 2
Liu, M., Qiu, Y., Xie, E., Qian, P., Yang, S., Zhao, S., Yan, W., Huang, X., & Han, S. (2025) · BMC Biotechnology · doi:10.1186/s12896-025-00970-w · Cited by 2
“Another important indicator recognized by the Whole Liver Society of Japan for early diagnosis of liver cancer is Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), primarily synthesized by the liver when there is a deficiency of vitamin K within the human body [13].”
Suzuki, T., Matsuura, K., Kato, D., Hayashi, K., Okayama, K., Okumura, F., Sobue, S., Kusakabe, A., Hasegawa, I., Narita, K., et al. (2025) · Oncology · doi:10.1159/000546515 · Cited by 2
“…of tyrosine kinase inhibitors (TKI), the terms “ Transcatheter Arterial Chemo-Embolization (TACE) refractory ” [9] and “ TACE unsuitable ” [10, 11] have been proposed to describe patient status in order to improve the prognosis of BCLC stage B u-HCC patients, and switching to TKIs contributed…”
MRI Imaging Biomarkers for Prognostication of Hepatocellular Carcinoma
Yoon, J. K., & Choi, J. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2025.0029 · Cited by 3
Matono, T., Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Liver International · doi:10.1111/liv.70217 · Cited by 2
“These discussions adhered to the Japanese clinical practice guidelines for HCC [10, 14].”
Self-citationNiitsu, H., Makishima, H., Hasegawa, N., Ikeda, T., Iizumi, T., SAITO, T. K., Numajiri, H., Nakai, K., Mizumoto, M., Okumura, T., et al. (2025) · Liver Cancer · doi:10.1159/000548347 · Cited by 2
Response Evaluation Criteria in Cancer of the Liver (RECICL 2021 revised version)
Kudo, M., Ikeda, M., Ueshima, K., Sakamoto, M., Shiina, S., Tateishi, R., Nouso, K., Hasegawa, K., Furuse, J., Miyayama, S., et al. (2021) · Kanzo · doi:10.2957/kanzo.62.823 · Cited by 2
Self-citationSaeki, I., Yamasaki, T., Yamauchi, Y., Kawaoka, T., Uchikawa, S., Hiramatsu, A., Aikata, H., Kobayashi, K., Kondo, T., Ogasawara, S., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5810 · Cited by 1
Self-citationHosoda, K., Toshima, T., Takahashi, J., Yonemura, Y., Hisamatsu, Y., Hirose, K., Masuda, T., Motomura, Y., Abe, T., Ando, Y., et al. (2023) · International Cancer Conference Journal · doi:10.1007/s13691-023-00618-6 · Cited by 2
Han, S., Kim, S. W., Park, S., Yoon, J. H., Kang, H., Yoo, J., Joo, I., Bae, J. S., & Lee, J. M. (2023) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2023.07.001 · Cited by 2
Qiao, W., Fan, Z., Wang, Q., Jin, R., & Hu, C. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s441540 · Cited by 2
Chrysavgis, L., & Cholongitas, Ε. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00020-5 · Cited by 3
Wang, X., Luo, T., Lu, S., Lu, H.-Z., Jiang, Z., Liu, X., Zhao, C., Li, L., & Chen, J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4141631 · Cited by 2
Kudo, M. (2024) · Liver Cancer · doi:10.1159/000543245 · Cited by 2
Self-citationEditorial: PIVKA‐II Facilitates Risk Stratification for HCC Following HCV Cure
Su, T., & Liao, W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18444 · Cited by 2
“AFP is recommended by the APASL and AASLD guidelines [6, 7] but only conditionally recommended by the EASL guideline [8], whereas PIVKAII is only endorsed by Japanese guidelines [9].”
Lilly, A. J., Patel, P., & Zhu, L. (2022) · Human Pathology Reports · doi:10.1016/j.hpr.2022.300597 · Cited by 1
Sasaki, K., Kawamura, Y., Ogawa, C., Yabushita, K., Watanabe, S., Hayashi, H., Kochi, T., Tomonari, T., Ninomiya, M., Takai, K., et al. (2024) · Cureus · doi:10.7759/cureus.57800 · Cited by 1
“They are recommended for unresectable HCC based on the liver cancer treatment guidelines of every country and are recognized as one [1,2].”
BackgroundSelf-citationZhu, G., Zeng, L., Liu, Y., Zhang, X., Tang, J., Pan, Y., Li, B., Chen, M., & Wu, T. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03718-1 · Cited by 2
“Although some current guidelines or consensus recommend Atez/Bev as the primary systemic chemotherapy and LEN as a secondary selection [12–14], some current studies have different conclusions [15–17], so it is necessary to conduct a systematic meta-analysis to provide a basis for the medication of…”
Xiao, Y., & Hu, Y. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01233-3 · Cited by 1
“Currently, the medical community considers TACE failure/refractoriness if there is no response after two consecutive or more TACE treatments [6].”
He, Z., Zhang, X., Zhang, Y., & Kong, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1413696 · Cited by 1
Precise liver tumor ablation: the clinical potential of US-US overlay fusion guidance
Minami, Y. (2024) · ULTRASONOGRAPHY · doi:10.14366/usg.24133 · Cited by 1
Self-citationNomogram to Predict Tumor Remnant of Small Hepatocellular Carcinoma after Microwave Ablation
Qiu, C., Ma, Y., Xiao, M., Wang, Z., Wu, S., Han, K., & Wang, H. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.09.066 · Cited by 1
Long-term results of surgical treatment of hepatocellular cancer in Russian real practice
Петкау, В. В., Исмагилович, Р. Р., Анатольевич, М. А., Nurbekyan, G. V., Борисович, У. И., Александрович, К. А., Орлова, Р. В., Попова, Н. В., Диникин, М. С., Khlobystin, R. Y., et al. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-422 · Cited by 1
Chiang, C., Huang, K.-K., Lee, C., Hong, T., Wu, J.-S., Wu, H., Chang, T., Liu, Y., Chen, W.-T., Wang, C., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241312141 · Cited by 1
“18 Tumor morphology Patients diagnosed with unresectable HCC were classified into the infiltrative group through Eggel’s classification, the Liver Cancer Study Group of Japan classification, and by considering the following characteristics, as previously out-lined 9–11, 19–”
Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis
Park, J., & Yu, S. J. (2025) · Ewha Medical Journal · doi:10.12771/emj.2025.e4 · Cited by 2
Goto, R., Shimamura, T., Nakajima, T., Ogawa, K., Tanaka, K., Shimizu, T., Minami, R., Matsui, T., Akutsu, N., Sasaki, S., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14178 · Cited by 1
“24 The ALBI score has been reported to be a superior clinical scoring system for representing the liver functional reserve compared with the Child–Pugh score, particularly Child–Pugh A and B. 20 Indeed, the clinical prognostic factors of HCC patients are mainly associated with tumor burden and…”
Huang, X., Cao, X., Kong, Y., Tang, F., Cong, T., & Zhou, X. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s490439 · Cited by 2
“2 Transcatheter intra-arterial therapy, including transarterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC), is commonly used to manage intermediate to advanced stages of HCC. 3 TACE is the first-line treatment for intermediate-stage HCC, 4 while HAIC has shown promising efficacy for large…”
InfluentialIizuka, Y., Inoue, M., Kokubo, M., Sakamoto, T., Murofushi, K. N., Imagumbai, T., Shimizuguchi, T., Hiraoka, M., & Mizowaki, T. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02740-2 · Cited by 1
“However, the resection rate remains low due to factors such as tumor burden and anatomical challenges [6, 7], and most patients are treated with systemic chemotherapy or best supportive care [8, 9].”
Zhao, H., Mao, Y., Wang, H., Zhou, A., Yang, Z., Han, Y., Gong, L., Bi, X., Hao, C., Wang, X., et al. (2025) · Cancer Innovation · doi:10.1002/cai2.70006 · Cited by 1
Liu, C.-W., Lin, P., Teng, W., Chen, W.-T., Su, C., Hsieh, Y., Lin, C., Lin, C., & Lin, S. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s502922 · Cited by 1
“In our real-world study, HAIC combined with TKI therapy resulted in better survival outcomes than HAIC alone in patients with advanced HCC.”
InfluentialNiizeki, T., Mawatari, S., Shibata, M., Sasaki, R., Itoh, S., Shakado, S., Sugimoto, R., Morita, Y., Kuwashiro, T., Endo, M., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17024 · Cited by 1
“Thus, systemic therapy or combination therapy with TACE and systemic therapy provides more favorable outcomes compared with TACE monotherapy in these criteria [6, 9].”
Lu, W., Li, Z., Chen, P., Chen, B., Zhang, G., Yang, Z., & Hao, J. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06233-7 · Cited by 2
“Curative conversion (resection, curative TACE or ablation) should be initiated as soon as possible in intermediate-stage HCC patients who achieve a deep tumor response with ate-zolizumab-bevacizumab therapy (Kudo 2021).”
InfluentialTCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects
Zeng, W., Zhu, W., Yuan, G., Chen, J., Wang, Z., Hou, J., & Jiang, D. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04122-z · Cited by 3
“The criteria recommended by European and American guidelines are more restrictive compared to Asian guidelines [18–22].”
Jiang, B., Jing, X., Wang, Y., Zhu, X., Wang, J., Du, R., Lv, B., Wang, K., Gao, Z., & Yan, K. (2025) · La radiologia medica · doi:10.1007/s11547-025-02034-7 · Cited by 1
“…was made by pathology on repeat biopsy or surgical resection; (2) lesions at follow-up with an increase in diameter of more than 20% and an absolute increase of 5 mm or more [18]; or (3) they were diagnosed on the basis of typical imaging findings, clinical features or oncologic history [5, 19].”
Takemoto, H., Takigawa, H., Kotachi, T., Teshima, H., Tsuboi, A., Tanaka, H., Yamashita, K., Urabe, Y., Kuwai, T., & Oka, S. (2025) · JGH Open · doi:10.1002/jgh3.70226 · Cited by 1
Ivanova, I., Banova-Chakarova, S., Boykova-Valcheva, P., & Bocheva, Y. (2025) · Livers · doi:10.3390/livers5030036 · Cited by 1
Re-evaluating surgical strategies in Barcelona Clinic Liver Cancer-B hepatocellular carcinoma
Liapis, I., Ziogas, I. A., Theocharopoulos, C., Moris, D., Nydam, T. L., Gleisner, A., Schulick, R. D., & Tsoulfas, G. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i9.108970 · Cited by 1
Kitamura, Y., & Aoyagi, K. (2025) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70114 · Cited by 1
The Evolving Application of Ultrasound in the Precision Management of Small Hepatocellular Carcinoma
Guan, X., Hu, X., Han, H., Zhang, D., & Xu, H. (2025) · Advanced ultrasound in diagnosis and therapy · doi:10.26599/audt.2025.250094 · Cited by 1
Zheng, Q., Chen, S., Weng, J., Huang, H., Xu, X., & Cao, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-15383-3 · Cited by 1
Zhang, J., Zhang, Z., Wu, Q., Zeng, J., Liu, J., & Zeng, J. (2025) · European journal of medical research · doi:10.1186/s40001-025-03126-w · Cited by 1
“The incidence of portal vein tumor thrombosis (PVTT) has been reported to be as high as 44–62% [11], and hepatic vein tumor thrombosis (HVTT) is present in around 1.4–4.9% [12–15].”
InfluentialTan, C.-P., Lee, T., Lee, I., Wu, K., Liu, C., Chiu, N., Hsu, S., Lee, P., Wu, C.-J., Chi, C., et al. (2025) · Liver Cancer · doi:10.1159/000550105 · Cited by 1
“Tumor morphology of post-ablation recurrent tumors was classified into four types: simple nodular, simple nodular with extranodular growth, confluent multi-nodular, and infiltrative types [17, 18].”
Asahi, Y., Kakisaka, T., Orimo, T., Shimada, S., Nagatsu, A., Aiyama, T., Fujiyoshi, S., Sakamoto, Y., Fujii, Y., Yoshida, Y., et al. (2025) · Surgery Today · doi:10.1007/s00595-025-03217-5 · Cited by 1
“As the liver function declines, so too does the probability that HCC patients are likely to be candidates for further resection and other local treatments such as radiofrequency ablation and transcatheter arterial chemoembolization (TACE) [ 7–9].”
Yeung, R. W. L., Chiu, K. W. H., Chan, S.-K., Wong, N. S. M., Chen, W., Lee, V. W. Y., Lee, F. A. S., Chan, A. C. Y., & Chiang, C. L. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.12.019 · Cited by 1
Yu, Z., You, R., Wang, C., Leng, B., Diao, L., Xu, Q., & Yin, G. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2025.47 · Cited by 1
Metadata
- Authors
- Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., Izumi, N., Moriguchi, M., Ogasawara, S., Minami, Y., Ueshima, K., Murakami, T., Miyayama, S., Nakashima, O., Yano, H., Sakamoto, M., Hatano, E., Shimada, M., Kokudo, N., Mochida, S., Takehara, T., & HCC Expert Panel of the Japan Society of Hepatology
- Affiliations
- Kindai University Hospital (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- Okayama City Hospital (JP)
- Juntendo University (JP)
- Ogaki Municipal Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- National Cancer Center Hospital East (JP)
- Musashino Red Cross Hospital (JP)
- Kyoto Prefectural University of Medicine (JP)
- Chiba University (JP)
- Kobe University (JP)
- Fukui-ken Saiseikai Hospital (JP)
- Kurume University (JP)
- Keio University (JP)
- Hyogo Medical University (JP)
- Tokushima University (JP)
- National Center for Global Health and Medicine (JP)
- Saitama Medical University (JP)
- The University of Osaka (JP)
- ORCID
- Kudo, Masatoshi
- Kawamura, Yusuke
- Hasegawa, Kiyoshi
- Tateishi, Ryosuke
- Kariyama, Kazuya
- Shiina, Shuichiro
- Toyoda, Hidenori
- Hiraoka, Atsushi
- Ikeda, Masafumi
- Izumi, Namiki
- Moriguchi, Michihisa
- Ogasawara, Sadahisa
- Minami, Yasunori
- Ueshima, Kazuomi
- Murakami, Takamichi
- Miyayama, Shiro
- Nakashima, Osamu
- Yano, Hirohisa
- Sakamoto, Michiie
- Hatano, Etsuro
- Shimada, Mitsuo
- Kokudo, Norihiro
- Mochida, Satoshi
- Takehara, Tetsuo
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 10
- Issue
- 3
- Pages
- 181-223
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC8237791
- OpenAlex
- W3162270595
- Cited by
- 678
- References
- 200
- Citations by year
- 2026: 78 · 2025: 137 · 2024: 158 · 2023: 177 · 2022: 108 · 2021: 17
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc)
- Funders
- Japan Society for the Promotion of Science (19K08199)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, consensus statement, clinical guidelines, HCC diagnosis, HCC treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.